5. Low Appetite / Nausea – While undergoing antiviral treatment for hepatitis, side effects include nausea and lack of appetite; it can even lead to vomiting in extreme situations. CBD oil can interact with serotonin receptors to help your stomach feel better, reducing the nausea brought on by treatment. This can lead to a better appetite and the ability to keep food down.
On top of that, its anti-inflammatory effects also help provide pain relief and improve cognitive activity.
CBD Oil and Hepatitis
2. Exhaustion – While CBD oil won’t provide you with more energy when you’re exhausted, what it will do is help you fall asleep at night. Those suffering from hepatitis are usually awake at night due to the stress of coping with the disease, so they can use something that can help them relax and fall asleep.
As already mentioned, CBD can help with many different ailments. But this article in particular will discuss how CBD oil can help those coping with hepatitis and its various symptoms.
CBD – is a cannabis byproduct that is becoming increasingly popular in the world of alternative medicine. CBD can be derived from both types of plants in the cannabis family: hemp and marijuana. While marijuana has a rather high amount of THC in it (the component that makes you high), hemp does not. CBD products contain little to no THC. Due to the low THC content and that marijuana is more difficult and expensive to grow, most of the CBD sold over the counter is derived from hemp.
While some early observational studies initially cautioned that heavy cannabis use among hepatitis C patients may adversely impact the liver, [8-10] more recent studies report that cannabis inhalation is not associated with the promotion of liver disease in hepatitis C subjects,  and, in some cases, may even act as a protective agent against it. [12-14] Specifically, a 2019 review of nine studies involving nearly six million subjects concluded, “Marijuana use [does] not increase the prevalence or progression of hepatic fibrosis in HCV and HCV-HIV-coinfected patients. On the contrary, we noted a reduction in the prevalence of NAFLD in marijuana users.” 
Patients diagnosed with hepatitis C frequently report using cannabis to treat both symptoms of the disease as well as the nausea associated with antiviral therapy. [5-6] An observational study by investigators at the University of California at San Francisco (UCSF) reports that hepatitis C patients who used cannabis were significantly more likely to adhere to their treatment regimen than patients who didn’t use it. 
 Ishida et al. 2008. Influence of cannabis use on severity of hepatitis C disease. Clinical Gastroenterology and Hepatology 6: 69-75.
Separate longitudinal data documents that patients co-infected with hepatitis C and HIV who consume cannabis are also less likely to suffer from insulin resistance as compared to non-users.  More notably, co-infected HIV/hepatitis C patients with a history of cannabis use possess a reduced mortality risk compared to non-users, according to the results of a five-year longitudinal study published in 2019 in the journal AIDS and Behavior. Authors of the study reported: “Regular/daily cannabis use, elevated coffee intake, and not currently smoking [tobacco] were independently associated with reduced HCV-mortality. … [P]otential benefits of cannabis-based therapies [should be further] investigated.” 
Hepatitis C is a viral disease of the liver that afflicts an estimated four million Americans. Chronic hepatitis C is typically associated with fatigue, depression, joint pain, and liver impairment, including cirrhosis and liver cancer.
Scientists suggest that the endocannabinoid system may moderate aspects of chronic liver disease. [1-2] Population data shows that adults with a history of cannabis use are less likely to suffer from specific liver problems, such as non-alcoholic fatty liver disease (NAFLD), than non-users. Specifically, a 2017 University of Massachusetts study reported that frequent consumers of cannabis were 52 percent less likely to be diagnosed with NAFLD as compared to non-users, while occasional consumers were 15 percent less likely to suffer from the disease.  A Stanford University study similarly reported that cannabis use independently predicted a lower risk of suspected NAFLD in a dose-dependent manner. “Active marijuana use provided a protective effect against NAFLD independent of known metabolic risk factors,” authors concluded. 
 Parfieniuk and Flisiak. 2008. Role of cannabinoids in liver disease. World Journal of Gastroenterology 14: 6109-6114.